4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Cash from Operations of 68125000.0 for Q1 2026, down 42.65% year-over-year from 118780393.19 in Q1 2025, and down 338.61% quarter-over-quarter from 28551000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Cash from Operations data on file, last reported at 68125000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 68125000.0, down 42.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 129449000.0 (up 15.53% YoY), and the FY2025 annual result was 109082000.0, up 18.95% from the prior year.
- Cash from Operations retreated to 68125000.0 in Q1 2026 per FDMT's latest filing, from 28551000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 28551000.0 in Q4 2025 and troughed at 68125000.0 in Q1 2026.
- A 5-year average of 27898176.47 and a median of 27906000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 2409.91% in 2024, then surged 162.25% in 2025.
- A 5-year view of Cash from Operations shows it stood at 22214000.0 in 2022, then dropped by 10.97% to 24650000.0 in 2023, then tumbled by 86.06% to 45863000.0 in 2024, then surged by 162.25% to 28551000.0 in 2025, then slumped by 338.61% to 68125000.0 in 2026.
- Business Quant data shows FDMT's Cash from Operations at 68125000.0 in Q1 2026, 28551000.0 in Q4 2025, and 46498000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -68.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.13 Mn |
| Mar 31, 2026 | -68.13 Mn |
| Dec 31, 2025 | 28.55 Mn |
| Dec 31, 2025 | 28.55 Mn |
| Sep 30, 2025 | -46.50 Mn |
| Sep 30, 2025 | -46.50 Mn |
| Jun 30, 2025 | -43.38 Mn |
| Jun 30, 2025 | -43.38 Mn |
| Mar 31, 2025 | -47.76 Mn |
| Mar 31, 2025 | -47.76 Mn |
| Dec 31, 2024 | -45.86 Mn |
| Dec 31, 2024 | -45.86 Mn |
| Sep 30, 2024 | -29.39 Mn |
| Sep 30, 2024 | -29.39 Mn |
| Jun 30, 2024 | -30.24 Mn |
| Jun 30, 2024 | -30.24 Mn |
| Mar 31, 2024 | -29.09 Mn |
| Mar 31, 2024 | -29.09 Mn |
| Dec 31, 2023 | -24.65 Mn |
| Dec 31, 2023 | -24.65 Mn |